Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial

Stock Information for Sera Prognostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sera Prognostics Inc.

Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024
SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION
SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES
SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.